IMBiotechnologies Ltd Announces Presentation at the 2018 Cardiovascular and Interventional Radiological Society of Europe Annual Meeting (Lisbon, Portugal)
About Occlusin 500
Occlusin 500 is a first-in-class biodegradable embolic agent that is detectable by ultrasound. It is a class II medical device cleared in the USA for the treatment of unresectable/inoperable hypervascularized tumors. IMBiotechnologies is currently seeking Health Canada approval for Occlusin 500.
About IMBiotechnologies Ltd.
IMBiotechnologies is a privately held Canadian medical device company located in Edmonton, Alberta focused on the commercialization of medical products in the area embolotherapy.
Embolotherapy works by reducing or eliminating the blood supply to target tissues. The procedure is performed by injecting embolic agents through a catheter into the blood vessels that feed the target tissue. By selectively blocking the tissue’s blood supply, the target tissue is either destroyed or devitalized, resulting in therapeutic benefit.
Kelly Mottet, 780-233-4294
Director of Marketing and Business Development
Source: IMBiotechnologies Ltd.